Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients-Reference-Cited by-同舟云学术

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Published:2010-11-30 Issue:12 Volume:62 Page:3607-3614
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Thurlings Rogier M.,Boumans Marie,Tekstra Janneke,van Roon Joel A.,Vos Koen,van Westing Daisy Marie,van Baarsen Lisa G.,Bos Carina,Kirou Kyriakos A.,Gerlag Danielle M.,Crow Mary K.,Bijlsma Johannes W.,Verweij Cornelis L.,Tak Paul P.

Funder

European Community Sixth Framework Programme (project AutoCure)

The Netherlands Genomics Initiative (IOP Genomics) from The Netherlands Organization for Scientific Research

Dutch Arthritis Association (Reumafonds)

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference44 articles.

1. Type I IFNs and their role in the development of autoimmune diseases;Burdick;Expert Opin Drug Saf,2009

2. Type I interferon in systemic lupus erythematosus;Crow;Curr Top Microbiol Immunol,2007

3. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients;Van der Pouw Kraan;Ann Rheum Dis,2007

4. Molecular subtypes of systemic sclerosis in association with anticentromere antibodies and digital ulcers;Bos;Genes Immun,2009

5. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis;Bilgic;Arthritis Rheum,2009

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Personalized Medicine in Rheumatoid Arthritis;Open Access Rheumatology: Research and Reviews;2024-05

2. Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies;Life Science Alliance;2023-03-06

3. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice;Annals of the Rheumatic Diseases;2023-03-01

4. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider;RMD Open;2023-03

5. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider;RMD Open;2023-03